Clintec Appoints Rick Farris

Posted On

September 12th, 2016: Clintec International announces the appointment of Rick Farris, Executive-Vice President of Operations for North America, as the organisation continues to successfully deliver on plans for growth in its clinical research capabilities in the USA.

With almost 30 years experience in the life sciences industry, Rick joins Clintec International from Novella Clinical, a Quintiles-owned company, where he held the position of Vice President in Project Management for the Biopharma and Rare Disease Business Unit. Rick provided client relationship management and project oversight for clinical trials in rare diseases, oncology, haematology, infectious disease, dermatitis, pain management, and gastroenterology.

Previously, he served as Chief Operating Officer at Health Decisions, a USA based CRO specialising in female reproductive health, rare disease, diagnostic devices, and oncology. Prior to his focus on clinical research, he worked within the healthcare technology industry providing solutions for patient information management, electronic health records, clinical management, and financial management within the clinical environment.

Mr Rick Farris commented:

“As Clintec’s Executive Vice-President of Operations for North America, I am thrilled to be joining the organization at a time of significant global growth, with the USA being a key market of strategic importance to our company. I look forward to working with Clintec’s executive leadership as well as the USA leadership team to expand further our presence in North America by providing highly responsive and top quality research services, seamlessly integrated with the outputs from our teams across the globe. With so many trials struggling with enrollment, particularly in rare disease and oncology, Clintec’s global footprint and permanent staff in 50 countries offers a unique opportunity for North American based companies needing to find patients wherever they are.”

The CEO and founder of Clintec International, Dr Rabinder Buttar remarked:

“As Clintec approaches its 20th year of significant organic growth, we are excited about our expansion plans in North America where we have a growing number of new clients. Rick will provide executive leadership to our teams and keep in close contact with our clients to ensure that as we continue to maintain our focus on high quality project delivery, remain highly responsive to client needs and provide a high level of customer service”.

Clintec International, a multi-award winning and privately owned Clinical Research Organisation (CRO), was formed nearly 20 years ago by its CEO and Chairman, Dr Rabinder Buttar. With capabilities in over 80 countries, Clintec delivers innovative, customised clinical research solutions and talented personnel resourcing to the clinical development sector in a fast, flexible and focused way. Clintec provides services to 7 of the world’s top 10 pharmaceutical companies, leading mid-market biopharmaceutical organisations, as well as small and medium-sized biotechnology companies. Through steady organic growth, Clintec has evolved into a recognised global player within the clinical research outsourcing arena and is the most geographically diverse mid-market CRO in the world, with an operating platform on a par to its multi-billion dollar competitors. Clintec has been recognised as the Best Mid-Sized Pharmaceutical CRO in the UK by Global Health and Pharma (GHP) Magazine’s 2016 International Life Sciences Awards and is a finalist in the Scale-up Business of the Year 2016 category for Minority Supplier Development UK’s (MSD UK) upcoming awards. Clintec’s success lies in a twofold approach through providing flexible, customised solutions which meet its clients’ needs, whilst at the same time creating an excellent working environment that supports and nurtures its staff.

You might also be interested in…